Twist Bioscience (TWST) Payables (2018 - 2026)

Twist Bioscience has disclosed Payables across 9 years of filings, most recently posting $14.7 million for Q1 2026.

• In Q1 2026, Payables rose 82.09% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $14.7 million (up 82.09% YoY), while the FY2025 annual figure was $11.1 million, up 580.61% from the prior year.
• Payables rose to $14.7 million in Q1 2026, from $12.5 million in the prior quarter.
• Over the last five years, Payables for TWST reached as high as $21.0 million in Q2 2022 and fell as low as $1.6 million in Q3 2024.
• The 5-year median for Payables is $12.1 million (2023), against an average of $12.2 million.
• Annual changes were most pronounced in 2023 — Payables sank 53.98% — and 2025, when it surged 580.61%.
• A 5-year view of Payables shows it stood at $20.1 million in 2022, then slumped by 53.98% to $9.3 million in 2023, then fell by 18.94% to $7.5 million in 2024, then jumped by 66.51% to $12.5 million in 2025, then gained by 17.52% to $14.7 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $14.7 million, $12.5 million, and $11.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.